Squadron Capital Management Establishes 5% Stake in C4 Therapeutics, Inc. (CCCC)

On May 19, 2026, Squadron Capital Management, LLC, along with Squadron Master Fund LP, Matthew Sesterhenn, and William Blank, filed a Schedule 13G disclosing a new 5.0% ownership stake in C4 Therapeutics, Inc. (CCCC). The reporting entities collectively hold 5,550,000 shares of common stock. The filing indicates that Squadron Capital Management, LLC serves as the investment adviser to private funds, including Squadron Master Fund LP, which directly holds the shares. Mr. Sesterhenn and Mr. Blank, as partners of Squadron Capital Management, may be deemed to have shared voting and dispositive power over the securities. The ownership percentage is based on approximately 110.57 million shares outstanding as of May 1, 2026. The acquisition was made in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. This filing marks a significant new position for the group, crossing the 5% beneficial ownership threshold.